요로생식기감염 항생제 처방지침 편집하기 (부분)

===== 추가 참조문헌 =====
1. Hooton, T.M., Clinical practice. Uncomplicated urinary tract infection. N Engl J Med, 2012.
366(11): p. 1028-37.
<br>
2. The Korean Society of Infectious Diseases, The Korean Society for Chemotherapy, Korean
Association of Urogenital Tract Infection, The Korean Society of Clinical Microbiology,
Clinical guideline for the diagnosis and treatment of urinary tract infections: asymptomatic
bacteriuria, uncomplicated & complicated urinary tract infections, bacterial prostatitis. Infection
& Chemotherapy, 2011. 43: p. 1-25.
<br>
3. Gupta, K., et al., International clinical practice guidelines for the treatment of acute
uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases
Society of America and the European Society for Microbiology and Infectious Diseases.
Clin Infect Dis, 2011. 52(5): p. e103-20.
<br>
4. Neumann, I. and P. Moore, Pyelonephritis (acute) in non-pregnant women. BMJ Clin Evid,
2014. 2014.
<br>
5. Pietrucha-Dilanchian, P. and T.M. Hooton, Diagnosis, Treatment, and Prevention of Urinary
Tract Infection. Microbiol Spectr, 2016. 4(6).
<br>
6. Veve, M.P., et al., Comparison of fosfomycin to ertapenem for outpatient or step-down
therapy of extended-spectrum beta-lactamase urinary tract infections. Int J Antimicrob Agents,
2016. 48(1): p. 56-60.
<br>
7. Bader, M.S., M. Loeb, and A.A. Brooks, An update on the management of urinary tract
infections in the era of antimicrobial resistance. Postgrad Med, 2017. 129(2): p. 242-258.
<br>
8. Tamma, P.D., et al., The use of cefepime for treating AmpC beta-lactamase-producing
Enterobacteriaceae. Clin Infect Dis, 2013. 57(6): p. 781-8.
<br>
9. Wagenlehner, F.M., et al., Ceftolozane-tazobactam compared with levofloxacin in the treatment
of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind,
phase 3 trial (ASPECT-cUTI). Lancet, 2015. 385(9981): p. 1949-56.
<br>
10. Rodriguez-Bano, J., et al., beta-Lactam/beta-lactam inhibitor combinations for the treatment
of bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: a post
hoc analysis of prospective cohorts. Clin Infect Dis, 2012. 54(2): p. 167-74.
<br>
11. Ipekci, T., et al., Clinical and bacteriological efficacy of amikacin in the treatment of lower
urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia
coli or Klebsiella pneumoniae. J Infect Chemother, 2014. 20(12): p. 762-7.